Where cancer biology meets health equity, one post at a time.
How pharmaceutical pricing actually works — and why the gap between R&D cost and sticker price is where policy has the most leverage.
Precision medicine promises treatment tailored to your tumor's biology — but tailored treatment is only useful if you can access it.
A ground-level look at where New York's Medicaid system fails families financially, and why it only covers four types of cancer.
Walking through the pipeline from basic research to an approved, priced drug — and where affordability gets decided.
What touring a computational drug discovery platform teaches you about speed, cost, and where regulation still lags behind.
What a treat-regardless-of-ability-to-pay pediatric practice can teach larger healthcare systems about access.
Who actually gets enrolled in cancer clinical trials, and why geography and income shape access as much as diagnosis does.
My flagship policy piece — three specific, actionable proposals rather than just a diagnosis of the problem.
